Spyre Therapeutics (SYRE) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.49
- EPS estimate
- −$0.75
- EPS surprise
- +34.98%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 5, 2025
Spyre Therapeutics' most recent results in the table are for Q2 2025, reported on August 5, 2025. It posted a loss of $0.49 per share, narrower than the expected loss of $0.75, a 34.98% beat. No revenue was reported and no revenue estimate was given. A year earlier, in Q2 2024, the loss was $0.86 per share.
Every one of the 20 quarters in the table, back to Q3 2020, was a loss. Per-share losses were much larger in earlier years: annual losses were $25.00 per share in 2021, $25.33 in 2022 and $75.14 in 2023, with the largest single quarter at a $56.75 loss in Q2 2023. The 2024 annual loss was $4.23 per share, and the first half of 2025 came to $1.09, against $2.06 in the first half of 2024. Revenue was small and is missing from Q3 2023 onward. Spyre beat the EPS estimate in 9 of the 20 quarters, including the last three.
The table has no quarter after Q2 2025. In past years, third-quarter results came in early November and fourth-quarter results between late February and mid-March. Newer quarters will show whether the per-share loss keeps narrowing.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$0.75 | −$0.49 | +34.98% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.84 | −$0.60 | +28.66% | $0.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.99 | −$0.81 | +17.86% | $0.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.82 | −$1.36 | −64.99% | $0.00 | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.95 | −$0.86 | +9.45% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$1.05 | −$1.20 | −14.41% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.73 | −$4.05 | −456.93% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.60 | −$9.34 | −1456.67% | $0.00 | SEC |
| Q2 2023 | Aug 11, 2023 | −$3.48 | −$56.75 | −1528.55% | $688,000.00 | SEC |
| Q1 2023 | May 11, 2023 | −$4.50 | −$5.00 | −11.11% | $198,000.00 | SEC |
| Q4 2022 | Mar 2, 2023 | −$5.71 | −$5.00 | +12.41% | $168,000.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$6.25 | −$4.33 | +30.79% | $174,000.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$7.95 | −$6.75 | +15.05% | $625,000.00 | — |
| Q1 2022 | May 5, 2022 | −$8.54 | −$9.25 | −8.37% | $1.4M | — |
| Q4 2021 | Mar 8, 2022 | −$7.19 | −$7.75 | −7.83% | $3.6M | SEC |
| Q3 2021 | Nov 4, 2021 | −$6.98 | −$7.75 | −11.03% | $1.4M | SEC |
| Q2 2021 | Aug 5, 2021 | −$4.11 | −$2.50 | +39.15% | $13.7M | SEC |
| Q1 2021 | May 10, 2021 | −$5.71 | −$7.00 | −22.50% | $0.00 | SEC |
| Q4 2020 | Mar 18, 2021 | −$7.68 | −$8.75 | −13.95% | $0.00 | SEC |
| Q3 2020 | Nov 5, 2020 | −$9.79 | −$7.25 | +25.97% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Spyre Therapeutics (SYRE) last report earnings?
Spyre Therapeutics last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did SYRE beat earnings estimates?
Yes. Spyre Therapeutics reported EPS of −$0.49 for Q2 2025 against a −$0.75 estimate — a 34.98% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.